MétaCan
Menu
← Back to cohort

What happens to men with prostate cancer whose PSA starts to rise while on neo-adjuvant androgen ablation therapy prior to external radiation?

2005· article· en· W2292883957 on OpenAlexaff
Paddy Niblock, Tom Pickles

Bibliographic record

VenueJournal of Clinical Oncology · 2005
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsMedicineProstate cancerUrologyRadiation therapyAndrogen suppressionExternal beam radiationCancerInternal medicineGynecology

Abstract

fetched live from OpenAlex

4644 Background: The purpose of this study is to assess the impact of a rising PSA after an initial response while on neo-adjuvant androgen ablation (NAAA) prior to external beam radiation therapy (EBRT) for prostate cancer. Methods: Between January 1995 and June 2000, from a prospectively collected database of 858 patients, we identified 183 patients who received between 3 and 12 months of NAAA prior to definitive EBRT and who had at least three PSA readings during this time. 151 (82.5%) had PSA values which continued to fall (Group 1) but 32 patients (17.5%) had a PSA that started to rise, after an initial fall (Group 2). A rise was defined as a PSA above the previous level, of magnitude at least 2 standard deviations greater than the assay sensitivity. The two groups were compared using Mann Whitney U and Pearson Chi squared tests. Kaplan-Meier and Log Rank analyses were performed for biochemical failure (bNED, using the Houston criterion), cause-specific survival (CSS) and overall survival (OS). Results: There was no statistically significant difference between the two groups in terms of radiation dose (68Gy), duration of hormonal therapy, T stage, Gleason score or risk group stratification. Base-line PSA, prior to any treatment, was significantly higher in Group 2 (median 21 v 13, p=0.017) and men in this group were 2.5 years younger (p= 0.02). The era of treatment was the same for both groups and the median follow-up was 63.5 months for Group 1 and 50 months for Group 2. Patients who sustained a PSA rise during the NAAA period had an increased incidence of PSA relapse (bNED 41% v 57% at 7 years, p=0.018), a trend towards poorer CSS (7 year rate 79% v 88%, p=0.091), and poorer overall survival (66% v 81%, p=0.037 at 7 years). Conclusions: A subset of patients treated with NAAA prior to EBRT develop a rising PSA profile that may represent androgen resistance. This is associated with a significantly worse outcome. PSA monitoring during the NA period is recommended. Such men may benefit from intensification of therapy and/or experimental intervention such as clustering anti-sense oligonucleotide therapy. No significant financial relationships to disclose.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.008
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.008
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0010.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.097
GPT teacher head0.477
Teacher spread0.380 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2005
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicProstate Cancer Treatment and Research→French-language works237,207→